Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Lloyd Kelland

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Anatomy

Disorders

Ovarian Neoplasms

Procedures

Physiology

Living Beings

Concepts & Ideas

Structure-Activity Relationship

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
18
Murrer, BA
14
Neidle, Stephen
14
Raynaud, Florence
12
Sharp, SY
10
Gowan, Sharon
9
Hartley, John
9
Workman, Paul
8
Thurston, David
8
Valenti, Melanie
8
Howard, Philip
7
O'Neill, CF
7
Goddard, Phyllis
7
Boxall, Frances
7
Read, Martin
7
Reszka, Anthony

Sign-in to see all Coauthors

Publications

TOP 3
Gunaratnam Mekala; Green Colin; Moreira João Bruno; Moorhouse Adam D; Kelland Lloyd R; Moses John E; Neidle Stephen
G-quadruplex compounds and cis-platin act synergistically to inhibit cancer cell growth in vitro and in vivo.
Hegmans Alexander; Kasparkova Jana; Vrana Oldrich; Kelland Lloyd R; Brabec Viktor; Farrell Nicholas P
Amide-based prodrugs of spermidine-bridged dinuclear platinum. Synthesis, DNA binding, and biological activity.
Kelland Lloyd
Targeting the limitless replicative potential of cancer: the telomerase/telomere pathway.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Lloyd Kelland (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Gunaratnam Mekala; Green Colin; Moreira João Bruno; Moorhouse Adam D; Kelland Lloyd R; Moses John E; Neidle Stephen
G-quadruplex compounds and cis-platin act synergistically to inhibit cancer cell growth in vitro and in vivo.
Biochemical pharmacology 2009;78(2):115-22.
2008: Hegmans Alexander; Kasparkova Jana; Vrana Oldrich; Kelland Lloyd R; Brabec Viktor; Farrell Nicholas P
Amide-based prodrugs of spermidine-bridged dinuclear platinum. Synthesis, DNA binding, and biological activity.
Journal of medicinal chemistry 2008;51(7):2254-60.
2007: Kelland Lloyd
Targeting the limitless replicative potential of cancer: the telomerase/telomere pathway.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(17):4960-3.
2007: Kelland Lloyd
The resurgence of platinum-based cancer chemotherapy.
Nature reviews. Cancer 2007;7(8):573-84.
2007: Kelland Lloyd
Broadening the clinical use of platinum drug-based chemotherapy with new analogues. Satraplatin and picoplatin.
Expert opinion on investigational drugs 2007;16(7):1009-21.
2007: Raynaud Florence I; Eccles Suzanne; Clarke Paul A; Hayes Angela; Nutley Bernard; Alix Sonia; Henley Alan; Di-Stefano Francesca; Ahmad Zahida; Guillard Sandrine; Bjerke Lynn M; Kelland Lloyd; Valenti Melanie; Patterson Lisa; Gowan Sharon; de Haven Brandon Alexis; Hayakawa Masahiko; Kaizawa Hiroyuki; Koizumi Tomonubu; Ohishi Takahide; Patel Sonal; Saghir Nahid; Parker Peter; Waterfield Mike; Workman Paul
Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.
Cancer research 2007;67(12):5840-50.
2007: Martelli Laura; Di Mario Francesco; Botti Paolo; Ragazzi Eugenio; Martelli Mario; Kelland Lloyd
Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status.
Biochemical pharmacology 2007;74(1):20-7.
2007: Zhao Liangli; Marshall Elaine S; Kelland Lloyd R; Baguley Bruce C
Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Investigational new drugs 2007;25(3):271-6.
2007: Martins Cristina; Gunaratnam Mekala; Stuart John; Makwana Vaidahi; Greciano Olga; Reszka Anthony P; Kelland Lloyd R; Neidle Stephen
Structure-based design of benzylamino-acridine compounds as G-quadruplex DNA telomere targeting agents.
Bioorganic & medicinal chemistry letters 2007;17(8):2293-8.
2007: Kelland Lloyd
Drug evaluation: ADH-1, an N-cadherin antagonist targeting cancer vascularization.
Current opinion in molecular therapeutics 2007;9(1):86-91.
2006: Ireson Christopher R; Kelland Lloyd R
Discovery and development of anticancer aptamers.
Molecular cancer therapeutics 2006;5(12):2957-62.
2006: Kelland Lloyd
Discontinued drugs in 2005: oncology drugs.
Expert opinion on investigational drugs 2006;15(11):1309-18.
2006: McPhail Lesley D; McIntyre Dominick J O; Ludwig Christian; Kestell Philip; Griffiths John R; Kelland Lloyd R; Robinson Simon P
Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis.
Neoplasia (New York, N.Y.) 2006;8(3):199-206.
2006: Kelland Lloyd
EuroTIDES 2005--Sixth Annual IBC Conference.
IDrugs : the investigational drugs journal 2006;9(2):101-4.
2006: Nicoll Kathryn; Robertson Jane; Lant Neil; Kelland Lloyd R; Rogers Paul M; Robins David J
Synthesis and antimelanoma activity of reversed amide analogues of N-acetyl-4-S-cysteaminylphenol.
Oncology research 2006;16(2):97-106.
2005: Harris Amanda L; Yang Xiaohong; Hegmans Alex; Povirk Lawrence; Ryan John J; Kelland Lloyd; Farrell Nicholas P
Synthesis, characterization, and cytotoxicity of a novel highly charged trinuclear platinum compound. Enhancement of cellular uptake with charge.
Inorganic chemistry 2005;44(26):9598-600.
2005: Nutley B P; Smith N F; Hayes A; Kelland L R; Brunton L; Golding B T; Smith G C M; Martin N M B; Workman P; Raynaud F I
Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026.
British journal of cancer 2005;93(9):1011-8.
2005: Banerji Udai; Walton Michael; Raynaud Florence; Grimshaw Rachel; Kelland Lloyd; Valenti Melani; Judson Ian; Workman Paul
Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(19 Pt 1):7023-32.
2005: Ma Erin S F; Bates W Douglas; Edmunds Armistead; Kelland Lloyd R; Fojo Tito; Farrell Nicholas
Enhancement of aqueous solubility and stability employing a trans acetate axis in trans planar amine platinum compounds while maintaining the biological profile.
Journal of medicinal chemistry 2005;48(18):5651-4.
2005: Zhao Liangli; Ching Lai-Ming; Kestell Philip; Kelland Lloyd R; Baguley Bruce C
Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability.
International journal of cancer. Journal international du cancer 2005;116(2):322-6.
2005: Raynaud Florence I; Whittaker Steven R; Fischer Peter M; McClue Steven; Walton Michael I; Barrie S Elaine; Garrett Michelle D; Rogers Paul; Clarke Simon J; Kelland Lloyd R; Valenti Melanie; Brunton Lisa; Eccles Suzanne; Lane David P; Workman Paul
In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(13):4875-87.
2005: Kelland Lloyd R
Emerging drugs for ovarian cancer.
Expert opinion on emerging drugs 2005;10(2):413-24.
2005: McPhail Lesley D; Chung Yuen-Li; Madhu Basetti; Clark Simon; Griffiths John R; Kelland Lloyd R; Robinson Simon P
Tumor dose response to the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic resonance spectroscopy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(10):3705-13.
2005: Kelland Lloyd R
Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects.
European journal of cancer (Oxford, England : 1990) 2005;41(7):971-9.
2005: Ferguson Jillian; Rogers Paul M; Kelland Lloyd R; Robins David J
Synthesis and antimelanoma activity of sterically congested tertiary amide analogues of N-acetyl-4-S-cysteaminylphenol.
Oncology research 2005;15(2):87-94.
2004: Harrison R John; Reszka Anthony P; Haider Shozeb M; Romagnoli Barbara; Morrell James; Read Martin A; Gowan Sharon M; Incles Christopher M; Kelland Lloyd R; Neidle Stephen
Evaluation of by disubstituted acridone derivatives as telomerase inhibitors: the importance of G-quadruplex binding.
Bioorganic & medicinal chemistry letters 2004;14(23):5845-9.
2004: Incles Christopher M; Schultes Christoph M; Kempski Helena; Koehler Heike; Kelland Lloyd R; Neidle Stephen
A G-quadruplex telomere targeting agent produces p16-associated senescence and chromosomal fusions in human prostate cancer cells.
Molecular cancer therapeutics 2004;3(10):1201-6.
2004: Hartley John A; Spanswick Victoria J; Brooks Natalie; Clingen Peter H; McHugh Peter J; Hochhauser Daniel; Pedley R Barbara; Kelland Lloyd R; Alley Michael C; Schultz Robert; Hollingshead Melinda G; Schweikart Karen M; Tomaszewski Joseph E; Sausville Edward A; Gregson Stephen J; Howard Philip W; Thurston David E
SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.
Cancer research 2004;64(18):6693-9.
2004: Kelland L R
Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development.
European journal of cancer (Oxford, England : 1990) 2004;40(6):827-36.
2004: Varvaresou A; Iakovou K; Gikas E; Fichtner I; Fiebig H H; Kelland L R; Double J A; Bibby M C; Hendriks H R
Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
Anticancer research 2004;24(2B):907-19.
2004: Pors Klaus; Paniwnyk Zennia; Ruparelia Ketan C; Teesdale-Spittle Paul H; Hartley John A; Kelland Lloyd R; Patterson Laurence H
Synthesis and biological evaluation of novel chloroethylaminoanthraquinones with potent cytotoxic activity against cisplatin-resistant tumor cells.
Journal of medicinal chemistry 2004;47(7):1856-9.
2004: Hiorns L R; Bradshaw T D; Skelton L A; Yu Q; Kelland L R; Leyland-Jones B
Variation in RNA expression and genomic DNA content acquired during cell culture.
British journal of cancer 2004;90(2):476-82.
2004: Seddon Beatrice; Kelland Lloyd R; Workman Paul
Bioreductive prodrugs for cancer therapy.
Methods in molecular medicine 2004;90():515-42.
2003: Incles Christopher M; Schultes Christoph M; Kelland Lloyd R; Neidle Stephen
Acquired cellular resistance to flavopiridol in a human colon carcinoma cell line involves up-regulation of the telomerase catalytic subunit and telomere elongation. Sensitivity of resistant cells to combination treatment with a telomerase inhibitor.
Molecular pharmacology 2003;64(5):1101-8.
2003: Harrison R John; Cuesta Javier; Chessari Gianni; Read Martin A; Basra Sanji K; Reszka Anthony P; Morrell James; Gowan Sharon M; Incles Christopher M; Tanious Farial A; Wilson W David; Kelland Lloyd R; Neidle Stephen
Trisubstituted acridine derivatives as potent and selective telomerase inhibitors.
Journal of medicinal chemistry 2003;46(21):4463-76.
2003: Johnston Stephen R D; Hickish Tamas; Ellis Paul; Houston Stephen; Kelland Lloyd; Dowsett Mitch; Salter Janine; Michiels Bart; Perez-Ruixo Juan Jose; Palmer Peter; Howes Angela
Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2492-9.
2003: Urbaniak Michael D; Frost Lisa M; Bingham John P; Kelland Lloyd R; Hartley John A; Woolfson Derek N; Caddick Stephen
Chemical synthesis and cytotoxicity of dihydroxylated cyclopentenone analogues of neocarzinostatin chromophore.
Bioorganic & medicinal chemistry letters 2003;13(12):2025-7.
2003: Pérez José M; Kelland Lloyd R; Montero Eva I; Boxall Frances E; Fuertes Miguel A; Alonso Carlos; Navarro-Ranninger Carmen
Antitumor and cellular pharmacological properties of a novel platinum(IV) complex: trans-[PtCl(2)(OH)(2)(dimethylamine) (isopropylamine)].
Molecular pharmacology 2003;63(4):933-44.
2003: Kelland Lloyd R
Farnesyl transferase inhibitors in the treatment of breast cancer.
Expert opinion on investigational drugs 2003;12(3):413-21.
2003: Pearson Vikki C; Ferguson Jillian; Rogers Paul M; Kelland Lloyd R; Robins David J
Synthesis and antimelanoma activity of tertiary amide analogues of N-acetyl-4-S-cysteaminylphenol.
Oncology research 2003;13(11):503-12.
2002: Sharp S Y; O'Neill C F; Rogers P; Boxall F E; Kelland L R
Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin.
European journal of cancer (Oxford, England : 1990) 2002;38(17):2309-15.
2002: Vlachou Margarita; Tsotinis Andrew; Kelland Lloyd R; Thurston David E
An expeditious synthesis of cytotoxic pyrroloisoquinoline derivatives. Structure-activity comparative studies with isomeric pyrroloquinolines.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2002;17(3):139-43.
2002: Rogers P; Boxall F E; Allott C P; Stephens T C; Kelland L R
Sequence-dependent synergism between the new generation platinum agent ZD0473 and paclitaxel in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
European journal of cancer (Oxford, England : 1990) 2002;38(12):1653-60.
2002: Smith Vicki; Hobbs Stephen; Court William; Eccles Suzanne; Workman Paul; Kelland Lloyd R
ErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the HSP90 inhibitor geldanamycin.
Anticancer research 2002;22(4):1993-9.
2002: Smith Victoria; Rowlands Martin G; Barrie Elaine; Workman Paul; Kelland Lloyd R
Establishment and characterization of acquired resistance to the farnesyl protein transferase inhibitor R115777 in a human colon cancer cell line.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(6):2002-9.
2002: Berry Jane M; Howard Philip W; Kelland Lloyd R; Thurston David E
Synthesis and biological evaluation of an N10-Psec substituted pyrrolo[2,1-c][1,4]benzodiazepine prodrug.
Bioorganic & medicinal chemistry letters 2002;12(10):1413-6.
2002: Gowan Sharon M; Harrison John R; Patterson Lisa; Valenti Melanie; Read Martin A; Neidle Stephen; Kelland Lloyd R
A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity.
Molecular pharmacology 2002;61(5):1154-62.
2002: Rogers Paul M; Beale Philip J; Al-Moundhri Mansour; Boxall Frances; Patterson Lisa; Valenti Melanie; Raynaud Florence; Hobbs Steve; Johnston Stephen; Kelland Lloyd R
Overexpression of BclXL in a human ovarian carcinoma cell line: paradoxic effects on chemosensitivity in vitro versus in vivo.
International journal of cancer. Journal international du cancer 2002;97(6):858-63.
2002: Heald Robert A; Modi Chetna; Cookson Jenny C; Hutchinson Ian; Laughton Charles A; Gowan Sharon M; Kelland Lloyd R; Stevens Malcolm F G
Antitumor polycyclic acridines. 8.(1) Synthesis and telomerase-inhibitory activity of methylated pentacyclic acridinium salts.
Journal of medicinal chemistry 2002;45(3):590-7.
2001: Cocker H A; Hobbs S M; Tiffin N; Pritchard-Jones K; Pinkerton C R; Kelland L R
High levels of the MDM2 oncogene in paediatric rhabdomyosarcoma cell lines may confer multidrug resistance.
British journal of cancer 2001;85(11):1746-52.
2001: Kelland L R; Smith V; Valenti M; Patterson L; Clarke P A; Detre S; End D; Howes A J; Dowsett M; Workman P; Johnston S R
Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(11):3544-50.
2001: Hegmans A; Qu Y; Kelland L R; Roberts J D; Farrell N
Novel approaches to polynuclear platinum pro-drugs. Selective release of cytotoxic platinum-spermidine species through hydrolytic cleavage of carbamates.
Inorganic chemistry 2001;40(24):6108-14.
2001: Gregson S J; Howard P W; Corcoran K E; Jenkins T C; Kelland L R; Thurston D E
Synthesis of the first example of a C2-C3/C2'-C3'-endo unsaturated pyrrolo[2,1-c][1,4]benzodiazepine dimer.
Bioorganic & medicinal chemistry letters 2001;11(21):2859-62.
2001: Cocker H A; Tiffin N; Pritchard-Jones K; Pinkerton C R; Kelland L R
In vitro prevention of the emergence of multidrug resistance in a pediatric rhabdomyosarcoma cell line.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(10):3193-8.
2001: Masters J R; Thomson J A; Daly-Burns B; Reid Y A; Dirks W G; Packer P; Toji L H; Ohno T; Tanabe H; Arlett C F; Kelland L R; Harrison M; Virmani A; Ward T H; Ayres K L; Debenham P G
Short tandem repeat profiling provides an international reference standard for human cell lines.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(14):8012-7.
2001: Read M; Harrison R J; Romagnoli B; Tanious F A; Gowan S H; Reszka A P; Wilson W D; Kelland L R; Neidle S
Structure-based design of selective and potent G quadruplex-mediated telomerase inhibitors.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(9):4844-9.
2001: Gregson S J; Howard P W; Hartley J A; Brooks N A; Adams L J; Jenkins T C; Kelland L R; Thurston D E
Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity.
Journal of medicinal chemistry 2001;44(5):737-48.
2001: Lant N J; McKeown P; Timoney M C; Kelland L R; Rogers P M; Robins D J
Synthesis and anti-melanoma activity of analogues of N-acetyl-4-S-cysteaminylphenol substituted with two methyl groups alpha to the nitrogen.
Anti-cancer drug design 2001;16(1):49-55.
2000: Antonini I; Polucci P; Kelland L R; Spinelli S; Pescalli N; Martelli S
N4-(omega-Aminoalkyl)-1-[(omega-aminoalkyl)amino]-4- acridinecarboxamides: novel, potent, cytotoxic, and DNA-binding agents.
Journal of medicinal chemistry 2000;43(25):4801-5.
2000: Kelland L R
Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status.
Expert opinion on investigational drugs 2000;9(12):2903-11.
2000: Sharp S Y; Kelland L R; Valenti M R; Brunton L A; Hobbs S; Workman P
Establishment of an isogenic human colon tumor model for NQO1 gene expression: application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo.
Molecular pharmacology 2000;58(5):1146-55.
2000: Holford J; Beale P J; Boxall F E; Sharp S Y; Kelland L R
Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines.
European journal of cancer (Oxford, England : 1990) 2000;36(15):1984-90.
2000: Lant N J; McKeown P; Kelland L R; Rogers P M; Robins D J
Synthesis and antimelanoma activity of analogues of N-acetyl-4-S-cysteaminylphenol.
Anti-cancer drug design 2000;15(4):295-302.
2000: Gregson S J; Howard P W; Barcella S; Nakamya A; Jenkins T C; Kelland L R; Thurston D E
Effect of C2/C3-endo unsaturation on the cytotoxicity and DNA-binding reactivity of pyrrolo[2,1-c][1,4]benzodiazepines.
Bioorganic & medicinal chemistry letters 2000;10(16):1849-51.
2000: Gregson S J; Howard P W; Corcoran K E; Barcella S; Yasin M M; Hurst A A; Jenkins T C; Kelland L R; Thurston D E
Effect of C2-exo unsaturation on the cytotoxicity and DNA-binding reactivity of pyrrolo[2,1-c][1,4]benzodiazepines.
Bioorganic & medicinal chemistry letters 2000;10(16):1845-7.
2000: Qu Y; Rauter H; Soares Fontes A P; Bandarage R; Kelland L R; Farrell N
Synthesis, characterization, and cytotoxicity of trifunctional dinuclear platinum complexes: comparison of effects of geometry and polyfunctionality on biological activity.
Journal of medicinal chemistry 2000;43(16):3189-92.
2000: Cocker H A; Pinkerton C R; Kelland L R
Characterization and modulation of drug resistance of human paediatric rhabdomyosarcoma cell lines.
British journal of cancer 2000;83(3):338-45.
2000: Manzotti C; Pratesi G; Menta E; Di Domenico R; Cavalletti E; Fiebig H H; Kelland L R; Farrell N; Polizzi D; Supino R; Pezzoni G; Zunino F
BBR 3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(7):2626-34.
2000: Kelland L R
An update on satraplatin: the first orally available platinum anticancer drug.
Expert opinion on investigational drugs 2000;9(6):1373-82.
2000: Pestell K E; Hobbs S M; Titley J C; Kelland L R; Walton M I
Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line.
Molecular pharmacology 2000;57(3):503-11.
2000: Beale P J; Rogers P; Boxall F; Sharp S Y; Kelland L R
BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma.
British journal of cancer 2000;82(2):436-40.
2000: Judson I; Kelland L R
New developments and approaches in the platinum arena.
Drugs 2000;59 Suppl 4():29-36; discussion 37-8.
2000: Kelland L R
Preclinical perspectives on platinum resistance.
Drugs 2000;59 Suppl 4():1-8; discussion 37-8.
1999: O'Neill C F; Koberle B; Masters J R; Kelland L R
Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
British journal of cancer 1999;81(8):1294-303.
1999: O'Neill C F; Hunakova L; Kelland L R
Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
Chemico-biological interactions 1999;123(1):11-29.
1999: Read M A; Wood A A; Harrison J R; Gowan S M; Kelland L R; Dosanjh H S; Neidle S
Molecular modeling studies on G-quadruplex complexes of telomerase inhibitors: structure-activity relationships.
Journal of medicinal chemistry 1999;42(22):4538-46.
1999: Kelland L R; Sharp S Y; Rogers P M; Myers T G; Workman P
DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90.
Journal of the National Cancer Institute 1999;91(22):1940-9.
1999: Kelland L R
Meeting report on 8th International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy.
Journal of inorganic biochemistry 1999;77(1-2):121-4.
1999: Kelland L R; Sharp S Y; O'Neill C F; Raynaud F I; Beale P J; Judson I R
Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance.
Journal of inorganic biochemistry 1999;77(1-2):111-5.
1999: Hiorns L R; Seckl M J; Paradinas F; Sharp S Y; Skelton L A; Brunstrom G; Newlands E S; Kelland L R; Leyland-Jones B
A molecular cytogenetic approach to studying platinum resistance.
Journal of inorganic biochemistry 1999;77(1-2):95-104.
1999: Wilson S C; Howard P W; Forrow S M; Hartley J A; Adams L J; Jenkins T C; Kelland L R; Thurston D E
Design, synthesis, and evaluation of a novel sequence-selective epoxide-containing DNA cross-linking agent based on the pyrrolo[2, 1-c][1,4]benzodiazepine system.
Journal of medicinal chemistry 1999;42(20):4028-41.
1999: Harrison R J; Gowan S M; Kelland L R; Neidle S
Human telomerase inhibition by substituted acridine derivatives.
Bioorganic & medicinal chemistry letters 1999;9(17):2463-8.
1999: Perry P J; Gowan S M; Read M A; Kelland L R; Neidle S
Design, synthesis and evaluation of human telomerase inhibitors based upon a tetracyclic structural motif.
Anti-cancer drug design 1999;14(4):373-82.
1999: Perry P J; Read M A; Davies R T; Gowan S M; Reszka A P; Wood A A; Kelland L R; Neidle S
2,7-Disubstituted amidofluorenone derivatives as inhibitors of human telomerase.
Journal of medicinal chemistry 1999;42(14):2679-84.
1999: Antonini I; Polucci P; Kelland L R; Menta E; Pescalli N; Martelli S
2,3-Dihydro-1H,7H-pyrimido[5,6,1-de]acridine-1,3,7-trione derivatives, a class of cytotoxic agents active on multidrug-resistant cell lines: synthesis, biological evaluation, and structure-activity relationships.
Journal of medicinal chemistry 1999;42(14):2535-41.
1999: Leyland-Jones B; Kelland L R; Harrap K R; Hiorns L R
Genomic imbalances associated with acquired resistance to platinum analogues.
The American journal of pathology 1999;155(1):77-84.
1999: Kelland L R
Small molecule anticancer drugs.
IDrugs : the investigational drugs journal 1999;2(6):550-2.
1999: Thurston D E; Bose D S; Howard P W; Jenkins T C; Leoni A; Baraldi P G; Guiotto A; Cacciari B; Kelland L R; Foloppe M P; Rault S
Effect of A-ring modifications on the DNA-binding behavior and cytotoxicity of pyrrolo[2,1-c][1,4]benzodiazepines.
Journal of medicinal chemistry 1999;42(11):1951-64.
1999: Perez J M; Camazón M; Alvarez-Valdes A; Quiroga A G; Kelland L R; Alonso C; Navarro-Ranninger M C
Synthesis, characterization and DNA modification induced by a novel Pt(IV)-bis(monoglutarate) complex which induces apoptosis in glioma cells.
Chemico-biological interactions 1999;117(2):99-115.
1998: Perry P J; Reszka A P; Wood A A; Read M A; Gowan S M; Dosanjh H S; Trent J O; Jenkins T C; Kelland L R; Neidle S
Human telomerase inhibition by regioisomeric disubstituted amidoanthracene-9,10-diones.
Journal of medicinal chemistry 1998;41(24):4873-84.
1998: Henderson N D; Lacy S M; O'Hare C C; Hartley J A; McClean S; Wakelin L P; Kelland L R; Robins D J
Synthesis of new bifunctional compounds which selectively alkylate guanines in DNA.
Anti-cancer drug design 1998;13(7):749-68.
1998: Pestell K E; Medlow C J; Titley J C; Kelland L R; Walton M I
Characterisation of the p53 status, BCL-2 expression and radiation and platinum drug sensitivity of a panel of human ovarian cancer cell lines.
International journal of cancer. Journal international du cancer 1998;77(6):913-8.
1998: Kelland L
DNA-interactive agents.
IDrugs : the investigational drugs journal 1998;1(4):397-8.
1998: Kelland L
Signal transduction pathways.
IDrugs : the investigational drugs journal 1998;1(4):394-6.
1998: Kelland L
NCI-EORTC - 10th Symposium - New approaches and cellular targets.
IDrugs : the investigational drugs journal 1998;1(4):391-3.
1998: Bradshaw T D; Shi D F; Schultz R J; Paull K D; Kelland L; Wilson A; Garner C; Fiebig H H; Wrigley S; Stevens M F
Influence of 2-(4-aminophenyl)benzothiazoles on growth of human ovarian carcinoma cells in vitro and in vivo.
British journal of cancer 1998;78(4):421-9.
1998: Perry P J; Gowan S M; Reszka A P; Polucci P; Jenkins T C; Kelland L R; Neidle S
1,4- and 2,6-disubstituted amidoanthracene-9,10-dione derivatives as inhibitors of human telomerase.
Journal of medicinal chemistry 1998;41(17):3253-60.
1998: Sharp S Y; Smith V; Hobbs S; Kelland L R
Lack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell lines.
British journal of cancer 1998;78(2):175-80.
1998: Holford J; Rogers P; Kelland L R
ras mutation and platinum resistance in human ovarian carcinomas in vitro.
International journal of cancer. Journal international du cancer 1998;77(1):94-100.
1998: Holford J; Raynaud F; Murrer B A; Grimaldi K; Hartley J A; Abrams M; Kelland L R
Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum co-ordination complex, cis-[amminedichloro(2-methylpyridine)] platinum(II) (AMD473).
Anti-cancer drug design 1998;13(1):1-18.
1998: Holford J; Sharp S Y; Murrer B A; Abrams M; Kelland L R
In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473.
British journal of cancer 1998;77(3):366-73.
1997: Raynaud F I; Boxall F E; Goddard P M; Valenti M; Jones M; Murrer B A; Abrams M; Kelland L R
cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(11):2063-74.
1997: Antonini I; Polucci P; Jenkins T C; Kelland L R; Menta E; Pescalli N; Stefanska B; Mazerski J; Martelli S
1-[(omega-aminoalkyl)amino]-4-[N-(omega-aminoalkyl)carbamoyl]-9-oxo-9, 10-dihydroacridines as intercalating cytotoxic agents: synthesis, DNA binding, and biological evaluation.
Journal of medicinal chemistry 1997;40(23):3749-55.
1997: McKeage M J; Raynaud F; Ward J; Berry C; O'Dell D; Kelland L R; Murrer B; Santabárabara P; Harrap K R; Judson I R
Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(7):2691-700.
1997: Köberle B; Grimaldi K A; Sunters A; Hartley J A; Kelland L R; Masters J R
DNA repair capacity and cisplatin sensitivity of human testis tumour cells.
International journal of cancer. Journal international du cancer 1997;70(5):551-5.
1997: Masters J R; Know R J; Hartley J A; Kelland L R; Hendriks H R; Connors T
KW-2149 (7-N-[2-[gamma-L-glutamylamino]ethyldithioethyl]mitomycin C). A new mitomycin C analogue activated by serum.
Biochemical pharmacology 1997;53(3):279-85.
1996: Ormerod M G; Orr R M; O'Neill C F; Chwalinski T; Titley J C; Kelland L R; Harrap K R
The cytotoxic action of four ammine/amine platinum(IV) dicarboxylates: a flow cytometric study.
British journal of cancer 1996;74(12):1935-43.
1996: Buckley R G; Elsome A M; Fricker S P; Henderson G R; Theobald B R; Parish R V; Howe B P; Kelland L R
Antitumor properties of some 2-[(dimethylamino)methyl]phenylgold(III) complexes.
Journal of medicinal chemistry 1996;39(26):5208-14.
1996: O'Neill C F; Ormerod M G; Robertson D; Titley J C; Cumber-Walsweer Y; Kelland L R
Apoptotic and non-apoptotic cell death induced by cis and trans analogues of a novel ammine(cyclohexylamine)dihydroxodichloroplatinum(IV) complex.
British journal of cancer 1996;74(7):1037-45.
1996: Raynaud F I; Odell D E; Kelland L R
Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels.
British journal of cancer 1996;74(3):380-6.
1996: Raynaud F I; Boxall F E; Goddard P; Barnard C F; Murrer B A; Kelland L R
Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products.
Anticancer research 1996;16(4A):1857-62.
1996: Goddard P M; Orr R M; Valenti M R; Barnard C F; Murrer B A; Kelland L R; Harrap K R
Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours.
Anticancer research 1996;16(1):33-8.
1996: Walton M I; Goddard P; Kelland L R; Thurston D E; Harrap K R
Preclinical pharmacology and antitumour activity of the novel sequence-selective DNA minor-groove cross-linking agent DSB-120.
Cancer chemotherapy and pharmacology 1996;38(5):431-8.
1996: Aherne G W; Hardcastle A; Valenti M; Bryant A; Rogers P; Pettit G R; Srirangam J K; Kelland L R
Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay.
Cancer chemotherapy and pharmacology 1996;38(3):225-32.
1996: Raynaud F I; Mistry P; Donaghue A; Poon G K; Kelland L R; Barnard C F; Murrer B A; Harrap K R
Biotransformation of the platinum drug JM216 following oral administration to cancer patients.
Cancer chemotherapy and pharmacology 1996;38(2):155-62.
1995: Sharp S Y; Rogers P M; Kelland L R
Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(9):981-9.
1995: Poon G K; Raynaud F I; Mistry P; Odell D E; Kelland L R; Harrap K R; Barnard C F; Murrer B A
Metabolic studies of an orally active platinum anticancer drug by liquid chromatography-electrospray ionization mass spectrometry.
Journal of chromatography. A 1995;712(1):61-6.
1995: Mellish K J; Barnard C F; Murrer B A; Kelland L R
DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines.
International journal of cancer. Journal international du cancer 1995;62(6):717-23.
1995: Kelland L R; Barnard C F; Evans I G; Murrer B A; Theobald B R; Wyer S B; Goddard P M; Jones M; Valenti M; Bryant A
Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes.
Journal of medicinal chemistry 1995;38(16):3016-24.
1995: Kelland L R; Kimbell R; Hardcastle A; Aherne G W; Jackman A L
Relationships between resistance to cisplatin and antifolates in sensitive and resistant tumour cell lines.
European journal of cancer (Oxford, England : 1990) 1995;31A(6):981-6.
1995: Jackman A L; Kelland L R; Kimbell R; Brown M; Gibson W; Aherne G W; Hardcastle A; Boyle F T
Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.
British journal of cancer 1995;71(5):914-24.
1995: McKeage M J; Mistry P; Ward J; Boxall F E; Loh S; O'Neill C; Ellis P; Kelland L R; Morgan S E; Murrer B
A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration.
Cancer chemotherapy and pharmacology 1995;36(6):451-8.
1994: Mellish K J; Kelland L R
Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines.
Cancer research 1994;54(23):6194-200.
1994: Kelland L R; Barnard C F; Mellish K J; Jones M; Goddard P M; Valenti M; Bryant A; Murrer B A; Harrap K R
A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity.
Cancer research 1994;54(21):5618-22.
1994: Mellish K J; Barnard C F; Kelland L R; Harrap K R
Circumvention of acquired tetraplatin resistance in a human ovarian carcinoma cell line by a novel trans platinum complex, JM335 [trans ammine (cyclohexylamine) dichloro dihydroxo platinum (IV)].
International journal of cancer. Journal international du cancer 1994;59(1):65-70.
1994: Sharp S Y; Rowlands M G; Jarman M; Kelland L R
Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines.
British journal of cancer 1994;70(3):409-14.
1994: McKeage M J; Kelland L R; Boxall F E; Valenti M R; Jones M; Goddard P M; Gwynne J; Harrap K R
Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo.
Cancer research 1994;54(15):4118-22.
1994: Kelland L R; McKeage M J
New platinum agents. A comparison in ovarian cancer.
Drugs & aging 1994;5(2):85-95.
1994: Goddard P; Valenti M; Kelland L R
The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts.
Anticancer research 1994;14(3A):1065-70.
1994: McKeage M J; Abel G; Kelland L R; Harrap K R
Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro.
British journal of cancer 1994;69(1):1-7.
1994: Raynaud F I; Kelland L R; Walton M I; Judson I R
Preclinical pharmacology of 1069C85, a novel tubulin binder.
Cancer chemotherapy and pharmacology 1994;35(2):169-73.
1994: Sharp S Y; Mistry P; Valenti M R; Bryant A P; Kelland L R
Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines by amphotericin B.
Cancer chemotherapy and pharmacology 1994;35(2):137-43.
1994: Kelland L R
The molecular basis of cisplatin sensitivity/resistance.
European journal of cancer (Oxford, England : 1990) 1994;30A(6):725-7.
1994: Aherne W; Hardcastle A; Kelland L; Jackman A
The measurement of deoxynucleotide (dNTP) pools by radioimmunoassay (RIA).
Advances in experimental medicine and biology 1994;370():801-4.
1993: Kelland L R
New platinum antitumor complexes.
Critical reviews in oncology/hematology 1993;15(3):191-219.
1993: Mistry P; Loh S Y; Kelland L R; Harrap K R
Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian-carcinoma cell lines.
International journal of cancer. Journal international du cancer 1993;55(5):848-56.
1993: Mellish K J; Kelland L R; Harrap K R
In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
British journal of cancer 1993;68(2):240-50.
1993: Kelland L R; Abel G; McKeage M J; Jones M; Goddard P M; Valenti M; Murrer B A; Harrap K R
Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
Cancer research 1993;53(11):2581-6.
1993: Gibson W; Bisset G M; Marsham P R; Kelland L R; Judson I R; Jackman A L
The measurement of polyglutamate metabolites of the thymidylate synthase inhibitor, ICI D1694, in mouse and human cultured cells.
Biochemical pharmacology 1993;45(4):863-9.
1993: Jones M; Siracky J; Kelland L R; Harrap K R
Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts.
British journal of cancer 1993;67(1):24-9.
1992: Loh S Y; Mistry P; Kelland L R; Abel G; Harrap K R
Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes.
British journal of cancer 1992;66(6):1109-15.
1992: Mistry P; Kelland L R; Loh S Y; Abel G; Murrer B A; Harrap K R
Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines.
Cancer research 1992;52(22):6188-93.
1992: Twentyman P R; Wright K A; Mistry P; Kelland L R; Murrer B A
Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin.
Cancer research 1992;52(20):5674-80.
1992: Kelland L R; Mistry P; Abel G; Loh S Y; O'Neill C F; Murrer B A; Harrap K R
Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.
Cancer research 1992;52(14):3857-64.
1992: Kelland L R; Mistry P; Abel G; Freidlos F; Loh S Y; Roberts J J; Harrap K R
Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line.
Cancer research 1992;52(7):1710-6.
1992: Kelland L R; Murrer B A; Abel G; Giandomenico C M; Mistry P; Harrap K R
Ammine/amine platinum(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines.
Cancer research 1992;52(4):822-8.
1992: Kelland L R; Jones M; Abel G; Valenti M; Gwynne J; Harrap K R
Human ovarian-carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discovery.
Cancer chemotherapy and pharmacology 1992;30(1):43-50.
1992: Kelland L R; Abel G
Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
Cancer chemotherapy and pharmacology 1992;30(6):444-50.
1991: McKeage M J; Higgins J D; Kelland L R
Platinum and other metal coordination compounds in cancer chemotherapy. A commentary on the sixth international symposium: San Diego, California, 23-26th January 1991.
British journal of cancer 1991;64(4):788-92.
1991: Mistry P; Kelland L R; Abel G; Sidhar S; Harrap K R
The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.
British journal of cancer 1991;64(2):215-20.
1991: Harrap K R; Kelland L R; Jones M; Goddard P M; Orr R M; Morgan S E; Murrer B A; Abrams M J; Giandomenico C M; Cobbleigh T
Platinum coordination complexes which circumvent cisplatin resistance.
Advances in enzyme regulation 1991;31():31-43.
1990: Harrap K R; Jones M; Siracky J; Pollard L A; Kelland L R
The establishment, characterization and calibration of human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer drugs.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1990;1(1):65-76.
1989: Hills C A; Kelland L R; Abel G; Siracky J; Wilson A P; Harrap K R
Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes.
British journal of cancer 1989;59(4):527-34.

Sign-in to see more